Primus In News
Novartis Vymada patent revoked, generics set to slash prices by 70%
17-09-2025
Nilaya Varma, Co-founder and Group CEO, Primus Partners, highlighted that Vymada holds a significant presence in India, with annual sales of around ₹550 crore. The Indian Patent Office’s decision to revoke Novartis’ patent, citing lack of novelty and technical advancement, is set to reshape the ₹550 crore market. This move is expected to open the floodgates for generics, potentially reducing prices by over 70% and improving access for millions of cardiovascular patients across the country.
Explore Related Insights
- Shaping the Future of Textile Education in India: Challenges, Opportunities, and the Path Forward
- Centre Looking To Chart Norms For 'Made In India' Firms That Can Take On Big 4
- FMCG, dairy and agri leaders welcome budget 2026 as catalyst for rural incomes & consumption
- Indian pharma eyes US gains as $63.7 bn patent cliff nears: Analysts
